Latest Insider Transactions at Iovance Biotherapeutics, Inc. (IOVA)
This section provides a real-time view of insider transactions for Iovance Biotherapeutics, Inc. (IOVA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IOVANCE BIOTHERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IOVANCE BIOTHERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 16
2023
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,835
+18.19%
|
-
|
|
Oct 16
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.13%
|
$4,185
$3.57 P/Share
|
|
Oct 16
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+7.69%
|
-
|
|
Oct 16
2023
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.65%
|
$4,185
$3.57 P/Share
|
|
Oct 16
2023
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+8.57%
|
-
|
|
Sep 18
2023
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+3.87%
|
$50,000
$5.56 P/Share
|
|
Sep 15
2023
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
5,000,000
+17.81%
|
$25,000,000
$5.3 P/Share
|
|
Jul 14
2023
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.88%
|
$9,765
$7.76 P/Share
|
|
Jul 14
2023
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+8.95%
|
-
|
|
Jul 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.31%
|
$9,765
$7.76 P/Share
|
|
Jul 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+8.0%
|
-
|
|
Jul 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-10.83%
|
$61,957
$7.76 P/Share
|
|
Jul 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+20.32%
|
-
|
|
Apr 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-12.7%
|
$44,255
$5.64 P/Share
|
|
Apr 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+23.01%
|
-
|
|
Apr 14
2023
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-5.13%
|
$6,975
$5.64 P/Share
|
|
Apr 14
2023
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+9.37%
|
-
|
|
Apr 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.51%
|
$6,975
$5.64 P/Share
|
|
Apr 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+8.33%
|
-
|
|
Jan 17
2023
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
36,441
-42.71%
|
$218,646
$6.43 P/Share
|
|
Jan 17
2023
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
83,325
+49.41%
|
-
|
|
Jan 17
2023
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,671
-16.08%
|
$28,026
$6.43 P/Share
|
|
Jan 17
2023
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,248
+27.91%
|
-
|
|
Jan 17
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,678
-14.26%
|
$28,068
$6.43 P/Share
|
|
Jan 17
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,248
+25.54%
|
-
|
|
Jan 03
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,023
-33.84%
|
$66,138
$6.11 P/Share
|
|
Jan 03
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,690
+37.68%
|
-
|
|
Jan 03
2023
|
Jean Marc Bellemin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,553
-37.22%
|
$63,318
$6.11 P/Share
|
|
Jan 03
2023
|
Jean Marc Bellemin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,850
+39.93%
|
-
|
|
Jan 03
2023
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,553
-37.22%
|
$63,318
$6.11 P/Share
|
|
Jan 03
2023
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,850
+39.93%
|
-
|
|
Dec 21
2022
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Direct |
10,000
+12.48%
|
$60,000
$6.15 P/Share
|
|
Dec 02
2022
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
10,000,000
+35.63%
|
$60,000,000
$6.5 P/Share
|
|
Nov 29
2022
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+4.02%
|
$60,000
$6.31 P/Share
|
|
Nov 28
2022
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+4.19%
|
$60,000
$6.18 P/Share
|
|
Nov 28
2022
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Open market or private purchase
|
Direct |
1,000
+33.33%
|
$5,000
$5.98 P/Share
|
|
Nov 23
2022
|
Iain D. Dukes Director |
BUY
Open market or private purchase
|
Direct |
10,000
+31.25%
|
$60,000
$6.1 P/Share
|
|
Aug 23
2022
|
Merrill A Mcpeak Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+39.94%
|
$200,000
$5.65 P/Share
|
|
Jun 14
2022
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,346
-49.58%
|
$65,422
$7.73 P/Share
|
|
Jun 14
2022
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,850
+50.0%
|
-
|
|
Jun 14
2022
|
Jean Marc Bellemin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,346
-49.58%
|
$65,422
$7.73 P/Share
|
|
Jun 14
2022
|
Jean Marc Bellemin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,850
+50.0%
|
-
|
|
Jun 14
2022
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,809
-34.58%
|
$47,663
$7.73 P/Share
|
|
Jun 14
2022
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,690
+50.0%
|
-
|
|
Jun 01
2022
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$6,000
$6.44 P/Share
|
|
Jun 01
2022
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+5.84%
|
$3,000,000
$6.43 P/Share
|
|
May 31
2022
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+6.2%
|
$3,000,000
$6.77 P/Share
|
|
May 31
2022
|
Michael Weiser Director |
BUY
Open market or private purchase
|
Direct |
10,000
+4.27%
|
$60,000
$6.8 P/Share
|
|
May 31
2022
|
Ryan D Maynard Director |
BUY
Open market or private purchase
|
Direct |
7,500
+50.0%
|
$45,000
$6.75 P/Share
|
|
May 31
2022
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+4.37%
|
$60,000
$6.8 P/Share
|